Skip to main content
ABION Inc. logo

ABION Inc. — Investor Relations & Filings

Ticker · 203400 ISIN · KR7203400007 KO Professional, scientific and technical activities
Open in API
Filings indexed 409 across all filing types
Latest filing 2024-01-04 Major Shareholding Noti…
Country KR South Korea
Listing KO 203400

About ABION Inc.

https://abionbio.com/en/

ABION Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative medicines, focusing on first-in-class and best-in-class therapeutics for oncology and viral diseases. The company's lead oncology asset is ABN401, a selective c-Met tyrosine kinase inhibitor (TKI) designed to treat non-small cell lung cancer (NSCLC) with MET mutations, which has shown a favorable safety profile. Another key pipeline candidate is ABN501, a novel monoclonal antibody targeting Claudin-3 for various cancers. Beyond oncology, ABION is developing ABN101, a second-generation Interferon-β formulated as a broad-spectrum anti-viral inhaler for respiratory infections. The company aims to commercialize its assets in global markets through internationally recognized clinical processes.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a standard regulatory filing in South Korea (often referred to as the 5% rule filing). It details the acquisition of shares by 'ST Fund No. 39' in the company 'Abion Inc.' (에이비온(주)). This type of filing is used to notify the market and regulators when a shareholder crosses a significant ownership threshold. In the provided classification schema, 'Major Shareholding Notification' (MRQ) is the correct category for such disclosures.
2024-01-04 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders (specifically Shin Young-kee and related parties) due to third-party capital increases and stock option exercises. This type of filing is a mandatory disclosure for significant shareholding changes and falls under the 'Major Shareholding Notification' category.
2024-01-03 Korean
증권발행결과(자율공시)(제3자배정 유상증자)
Share Issue/Capital Change Classification · 100% confidence The document is a formal announcement regarding the results of a third-party capital increase (share issuance) by the company Abion. It details the number of shares issued, the total amount raised, and the payment date. This falls under the category of share issuance and capital changes.
2023-12-28 Korean
증권발행결과(자율공시)(제3자배정 유상증자)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from a Korean company (Abion) announcing the results of a third-party capital increase (private placement). It details the number of shares issued, the amount raised, and the payment completion date. This falls under the category of share issuance and capital changes.
2023-12-26 Korean
주권관련사채권의취득결정(자율공시)
Capital/Financing Update Classification · 100% confidence The document is a regulatory filing from a Korean company (Abion) regarding the acquisition of convertible bonds issued by another company (Gencurix). It details the terms of the convertible bonds, including interest rates, conversion prices, and the purpose of the acquisition. This type of disclosure regarding financing activities and capital structure changes falls under the 'Capital/Financing Update' category.
2023-12-26 Korean
주권관련사채권의취득결정
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing titled '주권 관련 사채권의 취득결정' (Decision to Acquire Equity-Related Bonds/Convertible Bonds). It details the acquisition of convertible bonds issued by another company (Telcon RF Pharmaceutical) by the reporting company (Abion). It includes specific financial data, board resolution dates, terms of the convertible bonds (interest rates, conversion price, put options), and financial summaries of the issuer. This type of disclosure regarding capital investment and financing instruments is classified as a Capital/Financing Update.
2023-12-26 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.